Catheter Precision, Inc.
No SEC Form 4 filings for $VTAK in the last 30 days.
See all $VTAK insider activity →Catheter Precision Inc. (VTAK) is expanding its LockeT product commercialization across Latin America after a successful launch in Brazil. The company has partnered with a cardiology group to introduce LockeT in Argentina, Chile, and Colombia. LockeT is a suture retention device for wound closure, approved by the FDA and CE Mark. VTAK's stock is currently trading at $0.15, down 3.61%.
Catheter Precision, Inc. (VTAK) announced commercial milestones, including its first LockeT purchase order via Cardinal Health, which serves 90% of U.S. hospitals, and an order from Johns Hopkins. The company also placed its first VIVO 3D Imaging System in Germany, expanding its European presence. CEO David Jenkins highlighted the progress in distribution and clinical validation.
After-hours gains Monday lifted small-cap Catheter Precision (VTAK), Infleqtion (INFQ), and Oriental Rise Holdings (ORIS). VTAK rose nearly 61% after Flyte partnership with GSE Worldwide and Emiliano Grillo plus new heart-failure patents. INFQ jumped over 12% after Trump quantum executive orders and its Quantum Space Initiative. ORIS gained about 22% after a one-for-four reverse split took effect.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning VTAK (Catheter Precision, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent VTAK coverage spans financial news, corporate actions and technology.
The rollout may boost sales and market penetration for VTAK, supporting near‑term revenue growth.
The new distribution and hospital orders could boost sales volume and market penetration for VTAK's electrophysiology products.
Partnership plus new heart-failure patents are likely to sustain after-hours momentum and attract retail flow.
The filing signals an equity issuance under an exemption, which can increase share supply and affect near-term liquidity and dilution expectations.
The partnership is a fresh demand-generation catalyst for Flyte’s Cirrus Vision Jet network, likely supporting near-term sentiment and trading momentum.
AlphAI scores every news story that mentions VTAK with an AI model for sentiment and relevance, and aggregates insider trades from Catheter Precision, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Catheter Precision Inc. (VTAK) is expanding its LockeT product commercialization across Latin America after a successful launch in Brazil. The company has partnered with a cardiology group to introduce LockeT in Argentina, Chile, and Colombia. LockeT is a suture retention device for wound closure, approved by the FDA and CE Mark. VTAK's stock is currently trading at $0.15, down 3.61%.
1 min readCatheter Precision, Inc. (VTAK) announced commercial milestones, including its first LockeT purchase order via Cardinal Health, which serves 90% of U.S. hospitals, and an order from Johns Hopkins. The company also placed its first VIVO 3D Imaging System in Germany, expanding its European presence. CEO David Jenkins highlighted the progress in distribution and clinical validation.
1 min readAfter-hours gains Monday lifted small-cap Catheter Precision (VTAK), Infleqtion (INFQ), and Oriental Rise Holdings (ORIS). VTAK rose nearly 61% after Flyte partnership with GSE Worldwide and Emiliano Grillo plus new heart-failure patents. INFQ jumped over 12% after Trump quantum executive orders and its Quantum Space Initiative. ORIS gained about 22% after a one-for-four reverse split took effect.
3 min readCatheter Precision, Inc. (VTAK) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On July 30, 2026, Catheter Precision, Inc. (the “Company”) consummated the closing (the “Series C-4 Closing”) of the sale and issuance of an aggregate of 2,821 shares of the Company’s Series C-4 Convertible Preferred Stock, par v
3 min readFlyte (NYSE American: VTAK) announced a strategic partnership with 319 Golf Society, naming Flyte the Society’s exclusive private aviation partner. The company says 319 members get $1,000 toward their first Flyte trip plus merchandise and event access. Flyte will use its Cirrus Vision Jet fleet operated by FAA-certified Ponderosa Air, targeting short-haul travel between private clubs and resorts.
4 min readInvestorideas.com reports aviation-stock momentum tied to Fly Flyte, Inc., a Regional Air Mobility subsidiary of Catheter Precision, Inc. (VTAK). Flyte said it will partner with Blade Urban Air Mobility to feature its Cirrus Vision Jet fleet on Blade’s platform. The article also notes Blade’s integration into Uber and mentions JOBY and ACHR developments.
5 min readCatheter Precision’s (NYSE American: VTAK) Flyte unit said it partnered with Blade Urban Air Mobility to feature Flyte’s Cirrus Vision Jet fleet and charter offerings on Blade’s platform. The non-exclusive deal aims to expand distribution, increase aircraft utilization, and drive brand awareness and booking opportunities for regional travel.
3 min readCatheter Precision, Inc. (VTAK) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. EX-3.1 2 ex_988166.htm EXHIBIT 3.1 SERIES C-3 DESIGNATION ex_988166.htm Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C-3 CONVERTIBLE PREFERRED STOCK The undersigned, Philip Anderson, does hereby certify that: 1.
2 min readCatheter Precision, Inc. (VTAK) reported preliminary unaudited Q2 2026 revenues of $1.037 million for the quarter ended June 30, 2026. The MedTech segment rose 27% vs Q2 2025, while the Flyte Vision Jet segment increased 61% sequentially over Q1 2026 to $767,000. The company also cited over $400,000 in revenue for the first two weeks of July 2026.
3 min readCatheter Precision Inc. (VTAK) shares rose 19.36% to $0.67 after hours Tuesday after a 13.90% intraday drop to $0.56. Benzinga Pro data showed volume of 23.68M shares. The move followed a Jul. 10 SEC prospectus registering resale of 68.06M shares from preferred conversions and warrant exercises, warning of potential dilution.
4 min read
